The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...

US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis: Paris Thursday, February 26, 2026, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) ...

Indication covers kids and adults with a history of sino-nasal surgery ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and children aged 6 years and older supported by phase 3 study ...

LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).

Early symptoms that mimic common ear and sinus conditions often lead to delayed diagnosis.

Nasal polyps are benign growths often linked to chronic rhinosinusitis. Larger polyps can cause congestion, infections, and reduced smell. Surgery (polypectomy) removes polyps, but they often grow ...